GE HealthCare eyes next earnings date, shares tracked against medtech peers

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 09:42.

GE HealthCare (US36266G1076) sits in focus on the NYSE as investors look ahead to the next quarterly update and monitor how the medtech specialist compares with peers such as Siemens Healthineers and Philips. Analysts keep an eye on consensus expectations and rating distributions across the sector.

What analysts currently say

GE HealthCare Technologies is covered by a broad analyst community on Wall Street, with rating distributions providing a snapshot of how the market views the stock relative to other large-cap medtech names. Sector peers like Siemens Healthineers and Philips also attract regular coverage, giving investors comparative context for valuation and growth expectations.

Medtech peers in comparison

In the global medtech space, GE HealthCare competes for investor attention with companies such as Siemens Healthineers on Xetra and Philips on Euronext, both of which publish detailed earnings schedules and guidance updates that help shape sector sentiment. Rating trends across these peers offer retail investors additional data points when assessing relative performance and risk.

The product behind the stock

GE HealthCare generates revenue from medical imaging and diagnostics equipment, with ultrasound systems as one of its representative product lines used in hospitals and clinics worldwide. These systems support examinations in cardiology, obstetrics and general imaging, forming part of recurring hardware and service sales.

Where the stock trades today

GE HealthCare shares (US36266G1076) trade on the NYSE, with the latest verifiable price and market capitalization data accessible via the exchange and major financial portals as of the most recent trading session in US dollars.

Disclaimer: This article provides factual information and context on GE HealthCare Technologies Inc. It does not constitute investment advice, tax advice or a recommendation to buy or sell securities. Retail investors should perform their own research or consult a licensed advisor before making investment decisions.